Shattuck Labs Adds Industry Leaders to Board

By Tamara Parker • Monday, March 04 15:20 • Permanent Link

Shattuck Labs, Inc. (Shattuck) has announced the appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its board of directors, effective from March 1, 2024. Dr. Siegall is the President, Chief Executive Officer, and Chairman of the Board of Immunome, Inc., while Dr. Sasser is the Chief Scientific Officer of Tempus. Both bring a wealth of industry experience to Shattuck, with Dr. Siegall having a distinguished career in leadership and drug development, and Dr. Sasser having over 25 years of experience in translational research and precision medicine in biological sciences.

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. The company's lead SL-172154 (SIRPα-Fc-CD40L) program, designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials.

The addition of Dr. Siegall and Dr. Sasser to the board of directors comes as Shattuck progresses towards important inflection points, with the anticipation of continued expansion and future pivotal studies for SL-172154 in multiple indications. The company is poised for sustained growth as it aims to unlock further value from its proprietary agonist redirected checkpoint (ARC®) platform technology.

Dr. Siegall's impressive record of building and leading companies from drug discovery through commercialization, along with Dr. Sasser's drug development expertise, will be invaluable as Shattuck transitions to late-stage clinical development of SL-172154. This appointment comes at an appropriate time for the company as it looks forward to the next clinical updates expected mid-year.

Today the company's shares have moved -2.1% to a price of $9.45. For the full picture, make sure to review Shattuck Labs's 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.